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A new initia*ive  fo:r the aDbroxj-ma,tion of
_+*4#-,].-#-<+4--'
Ieeislation in the pharmaceu.ticals  sector
The Commi-ssion has considered it  necessary to request the Cor:ncil
to hold a, discussion not la,ter thsn in October so tha.t a, political
decision concerning the setting up of a conrnon market in pharmacer:tical
products may be taken before the end of the yee.r.  The Commission
reni-nded the President of the Council in  a, recent communicn,-rion  of the
neglectful way this  prohlem was bei-ng deaJ-t wi-th a;rd at the sarne time
submitted  a, working prograrnmeo  Now thal the technical. qrestions have
been thra.shed out by the erperts j.n disor:-soions lastlng for y633sr the
Cornmission considers that,  on the ba.sis of the new merilorandum  and the
proposed time-Iinits,  the Council should el?ress its  desire for the
approxima.ticn of legisl.ation to be continued.  .0Bproxima,tion cf
legisla*ion on the ph"gr'na,ce''rtlos], lumducts market ls  a par'ticui-arly
difficul.t  aspect of the efforts to crea.te ln the Common ldarket
conditions similar to those of a. domestic market"  Fcr seven years
ncw the Corrnunity institutions  ha,ve been striving to make heaCxey"
Ert this  sector is  also a striking  exampie of the aJ-mos''c connpic ie
sealing-off of markets by national laws.  As regards the effgc-b of
the legislation in guestior:, it  is  ertremely difficul*t  to disti.nguish
where economic interest ends and concern for the protec-l;ion of
peopl.eb heatth begi.nso The fundamental problern standing in 'bhe way
of the approxima,tion of the law appertaining to pha.:rmaceui;j.ca.1s  a"1so
lies here,  In the six member countries ntcre than 25 t)CO b::a,riilt:d
products, the so-calleC tpharmaceutical  speciali'tiesr (80/" ot' ti:e
total  market) are offered for sale.  Some of them are prodru"L;s whi.ch
are similar in composition and have the same therapeiltic effect but
are sold under different trade naneso On the otiter hand many ot':er
medicines are admitted only to one nttional marke'|, r:o tha.t they are
not available to all  pa,tients in the Conirn'mity  al.-bhor;.gh thci-r inproved
therapeutic effect ha.s been demonstrated" The pharmacetrticals
inCustry ha.s sought for ways out of this difficulty'  Atrrct:g other
things, it  has built  manufacturing plants in the various ccantries
a,nd ha,s thus alreadyttna.tionalizedrt  its  prod.rrcts at the"nap*2c;;t,J.:j;n6 lsve1 .
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However, this  is  impossibl-e without considerable investments
whose profitability  cannot always be optimalized from the angLe of
lusiness operations, with the result that a.n excessive cost structure
may have an unfavourable  effect on the sales price of the dmg.  The
production value of all  medica.rnents  produced in the Comrmrnity for
humar: therapy is  estimaied a;l approximately  3 000 milLion units of
account for 1!68.  In this connection it  is also inieresting to note
tha,t in Gerrnany, for  example, spending by households on health hes
risen more rapidly in the La.st six years than any other item of
expenditure.
ft  cannot be tolera.ted that a, continual.ly erpandlng branch of
industry should remain cut off  for an unforeseeable ti.me from the
advantages of a. free market r,lithin the Community. Nor can it  be
erpected of consumers of pha,rnaceuticels that they Eee anJr
ree.son why they shouLd be deprived of the common market as the widest
and cheapest possible source of best qrality  drugs.
The importa.nce of harmonizing legisla,tion for this market was
therefore recognized at a,n early date.  As far back a,s L962 the
Conrnission subrnitted a first  proposa,l for a directive to the Council.
1965 At the beginning of this year the Council adopted the first
directive.  ft  concerns the harmonization of licence and
registration  systems for the marketing of branded pharmaceuticals,
The Governments  made tbe authorization to tnarket a, drug subject
to t*id.e\r differing proc edures.
Although this directive has been in force for nearly
) years now, no Government has completely  transformed this
resclution into a nationa.l lal^r and implemented it.  Most
countries only made incomplete attempte and have been behind
schedule since 31 December 1"966,
L964 The second directive concerns the control and
of manufacturing and sale.  Discussions have
nothing.
J-966 In another directive the Comnission  proposed
of substances which are not to be all.owed a.s
drugs.  The Council dicl not take the matter
constant supervision




L967 The so-called third directive concerns the rnrtua^l recognition
of licences for the sale of branded pharmaceutioals.  The
Commission has meanwhile admitted thai the creation'of a, Corununity
s;i,stem calls for nnrch patience.,  Nevertheless, to ensure that- 3- P (6e) 49
consumers of pharmaceuticar products may a,s soon as possible
enjoy the advantages of conditions simiLar tc those in a
domestic market, the Commission proposed that }iember Sta,tes should
recognize the valldity  of the first  licence in the country of origin end merely cany out a. formaJ" check cn the d,ocuments sent to them by way of officiar  assistance.  rn this  case, the
Commission wishes to make use of a method whose rapid integrating effect has aJ-so been proved in other fields,
7967 The commissionts most lecent proposal- for a directive provides
that Member States should put on a uniform basis their  la.ws
concerning advertising  a,nd/or the limita.tion of certain
practices relating to sales promotion.
L969 F'ihally, leading scientists have herd numerous consultations
in which technical standards for tria.rs of new drugs h-ave been jointly  worked out.  These studies are a* present largely
concruded and in a,ll six countries the necessarSr rules could
now refer to these uniform standards and medical protocols
or incorpora.te them as an integral con:ponent.
Once already, in L967 in fact,
Council of the need to speed up the
d.t to pla.ce the item on its  a6enda.
obllged to note tha,t its  efforts had
the Commission  reminded the
discussions and requested
The Commission  wa,s
met with no success.
rn the same connection, the commission is  now making a further,
more thorough*going attempt.  Moreover, it  rnakes no secret of its
intention to institute  the prccedure refened to in Article  169 of
the Treaty aga,inst the Governments  in default if  they continue to
negl-ect their duties.  fhe commissionrs view is that it  is possible,
on the basis of the data, collected, to find a balanced, cornprehensive solution tha,t takes account of alr legitima.te interests.  it " requirements of public health and economic interests can therefore
be equal)-y provided for.  The commission believes tha.t this
objective crgr be a,chieved rapidly only if  the councir deoides on a precise vrorking progt.amme and a. binding time-table before the end of this autumn. ft  ha,s therefore proposed the following programme
to the Council.
Adoption of the second directi're (concerning the appl-ication for
eTiFffiFe for sale, the testing of the speciatity by the
manufacturer, and supervision) i
A{optSog of the third directive (concerning the r,mtual
recognition of licences for sate);
L.
Before 1 Januery 19702.
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4*o*!igg of the directive on the approximation of legislative
provisions governing substanceg wbich may be added to druge
as colorantsg
4SgB$93 of provisions on standards and protocoLs concerning
the .results of trials.
Before I  January 1971
Adoption of the directive on the advertising of pharmaceutical
specialities  and on the package inserts.
Sefore 1 Januarv 1971 _---
Adoption of ,the further directives stiLL
of a. common market in pharmaceutical
the programme).
needed for the establishment
specialities (see Par* 2 of
Prqposals to be sJ!4-bted by,thesornmlssicn
Before l_Jqjruary  L9?2
Submission of the further proposals for directives in fields in whlch
approxima,tion of la.ws and regu).etions is still  needed for the crea*ion
of a, common market in pharmaoeuticaJ- speciallties (conditions for tho
prescripti.on of medicines, prices, patentability);
Before 1 Jan'.rary I9I5
Submission of proposals -  baseC on a, study of e:ryerience of the  use
of the d.irective on recognition -  under which the procedure for the
cleclera*ion of validity  is  abandoned or a procedure for: the issue of
European licences directly  applicable throughout the Comrmrnity
territory  is  introduced.
Agtual implementa;bioq oJ the {egulations  adErted }y  the Cour-rcil
As, from I  {anuary_I97L
Apgli.calion of the first  directive (concerning  J.icence for sate);
jpp$S"Iigg of the second directive (concerning controls)9
Applic-":b:Lgg of standards and protocols for the results of trialsg
fnstitution of close co-operation between the competent authorities
in the l'{ember States, especially in order to exchange information  on
lessons learned in applying the first  two directives.
As from 1_ Janggrl_!9Z?
Apg$ggligg of the directive on colorants;
,[pplication of the third directive (concerning mutual recognition
r:4k
of-Iicences for sale);
Investigation of individual cases in which there are differences of
opinion between the l{ember Stetes conce?ning the issue or rescinding of
licences for sale in accordance roith the harmonized  1aw.
Ag frgg_.1 -rIgguryy 1971
Agp.licgllgg_of the directive on publicity.
Ls ,from I  ,renp,aryvj9J4 Ii-cation of the other
3.
directives still  needed for the establish-
in pharmaceutica"l specialities. of a comrnon marketTL -L-
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Une nouvelle initiative  Dour le  raoproche::ient des l6eislations  dans
1e secteu.r des sp6cialit6s  pharmaceutiques
La Commission a estim6 n6cessaire de deinander un d6bat au Conseil
avant le  31 octobre afin  qurune d6cision politique  puisse 6tre prise avant
La fin  de 1'ann6e sur lt6tabl-issement drun march6 commpn des sp6cialit6s
pharmaceutiques.  Elle  vient  de rappeler dans une lettre  au Pr6sident du
Conseil l-es retards apport6s A lfexamen de ce probldme et elle  a soumj-s
simultan6rnent un prograrnme de travail"  Les questions techniques ayant 6t6
discut6e A fond par les  extrlerts pendant des ann6es de n6gociations, iI  importe
maintenant, de ffavis  de la  Commlsslenl que-6ur la  base du nouveau  m6morandum
et des d61ais propos6s. le  Conseil exprime sa volont6 de poursuivre le  rappro-
chement des 16gisl-ations. Ce rapprochement des l6gislations  pour Ie  march6
des sp6cialit6s  pharmaceutiques constitue un chapitre particulidrement  dif-
ficile  dans les  efforts  en vue de cr6er dans le  march6 commun des conditions
analogues A ce]Ies dtun march6 int6rieur.  Depuis sept'ans fes i-nstitutions
communautaires srefforcent  de progresserr Mais ce secteur est aussi un exem-
ple frappant du cl-oisonnenent  quasl total- des march6s par 1es 16gis1atj-ons
nationales. Dans I'effet  de la  }€gislation,  iJ. est trds malais6 de disti-nguer
Ia part  des int6r6ts  6conomiques et'le  souci de prot6ger la  sant6 publique'
Ici  r6side aussi Ie  pnobl6me najeur du rapprochement des l6gislations  appJ,i-
cabl-es aux sp6cialj-t6s pharmaeeut{.ques.  Dans les six  pays membreso plus de
25.00O sp6cialit6s  pharnaceutiques  (BO % d^u vofume du march6) sont offertes
sur Ie niarch6. Certaines dtentre elles  sont des produj-ts de rn6me substance,
commercialis6s sous des appelletions diff6rentes  tout  en servant i  la  mGrne
th6rapeutique,  Beaucoup d'autres sp6cialit6s  ne sont autoris6es que sur un
march6 nati-onal et ne sont donq pas accessibles A. tous fes malades de la
Communaut6, bien quu lteffet  am6lior6 de ce rn6dicament ait  6t6 exp6rfunent6i
Lrindustrie  pharmaceutique a cherch6 des solutions notainment  en cr6ant dans
1es diff6""rris  pays des 6tablissements  de production et1 partant,  en rrnatj-o-
nalisantrr ses produits dbs le  'stade, de production. Mais il  faut  des investisse'
ments importants dont la  rentabilit6  ne peut pas toujours 6tre rendue optimale
selon d.es critdres  6conomi.quesi  de eorte q-urune structure de cofits trop  ,61e-
v6s peut avoir  des r6peicussions pr6judiciables sur le  prl-x de vente du m6dj--
camento La valeur de tous les m6dicaments produits pour Ia  m6decine hurnaine
est estim6e en 1958 A quelque J milliards 
-cl'UC dans fa  Communaut6 europ6enne"
A ce propos, il  est 6galernent interessant de noter quren A,11emagne, par exem-
ple,  1es d6penses de sant6 des m6nages ont progress6 plus rapidement que toutel
les autres d6penses au- cours de6,. gix, dernidres ann6ese
11 nrest pas admissible qufune ind.ustrie en expansion constante reste
exclue des avantages de 1a ]1bre circulation  intracomnunautaile,  11 n'est  pas
davantage  possj-ble drexiger des consommateurs  de sp6cialit6s  pharmaceutiques
qu t ils  acceptent de se voir  pr1v6s des avantages que leur  procure ]e  rnarch6
commun sous forme drune offre  auesL large et aussL avantageuse  que possible
de produits pharrnaceutiques'de  Ia meilleure qual-it6.
'  tl r/... {*.r
-2-
Crest pourquoi lfimportanee de itharmonisation des l6gislations  pour
ce march6 a 6t6 tr6s  t6t  reconnue. D,b."'1962, 1a Com:;risslon a sounis au
Conseil une premiBre proposition de directive  o
.  a-,
Au d6but de cette ann6e, 1,q;:Qofrseil a adopt6 la  premi6re directive"
Elle  concerne l-e rap'proahe'fiefit  ,dcs systdmes  d t autorisation  et  d 'en-
registremen-t  pou" 1;.' conmeicial-i.se!"ion dcs sp6cia1lt6s pharmaceuti-
que,s. Les gouvelnsfnents  soumette^ignt la  ntis-e sur le  march6 dtun m6di-
canent A des ]:roc6durcs entidrement diff6rcntes.
Bien que cette directive  sOit en vigueur depuis prds de 5 ansr aucun
gorr,r"in"*ent nta appli-qu,6 int6Sra}ement cette d6cision en la  reprenant
Iompldtement dans "o" d"oit  nadi,onal" La plupart  des pays nront entre-
prii  que des efforts  imparfaits ct  sont en retard  depuis Ie  31 d6cem-
bre 1956.
La deuxidme d.i-rective concerne le  contr6le et la  surveill-ance  constante
de Ia fabrication  et  de Ia  commerci-a]-isat,ion.  Les d6l-ib6rations sont
rest6res 
, juseu t ici  sans r6sultat '  ,
Dans une autre directive,  la,,lommissiqn a propos6 une iiste  europ6enne
interdisant  Iternploi de certair:s colorants dans les  m6dicaments'  Le
Consei-l nra pas ln"ore 
"om*uti,C6 ses d6l-ib6rat-ions sur cette proposition
ll^l::l :: :: : :l, : : ^ ;:-::,: :" 




";5 :;:: l: recon]'raassance  reoLproquc  q.eE
Commissior, "  "."'"o;;;-";,"etemps 
gUg fa realisation  d'un syst'}me comnu
nautaire exige beaucoup de patienie* Afin  cependant de garantir  aussi
rapi-dement que possiblL u.r, iorrsoruuatcur dc spcSciali-t6s pharmaceutiques
l-es avant-a.ges de conditions analogues A cclles  dlun march6 int6rieurt
elle  a propos6 que les Etats membres reconnaissent la  validit6  de 1a
premidri autorisation  dans X" p"yr dtorieine  et"se contentent de sou-
inettre ir un examen de form,e "lol  aonn6es transmi'ses  dans fe  cadre de
Itassistance adniinistrativC. La Commission entcnd ici  user d,rune mdtho-





La defnibre  proposition  de
il+^+^ *^';L-..^  *lacent  sur u  ud  uD  rrivilrwr  vD 
-l_,
ves i. la  publicit6  et A 1a
promotion des ventes,
.j-
dj-rective  de la  Comrnission pr6voit  que les
une base unlforme  leurs  l6gislations  relati-
limitation  de certaines  p:'atiques  dans la
!gP-  Enfip, de nonbrcuses discussions ont eu lieu  avec:des exp'erts 6minents'
I.-iTours de ces discussions, des normes techniques ont 6t6 61abor6es en commun
pour 1es e.ssais .des sp6cialit6s  phar',raceutiques nouvel1,qs.  Ces travaux
lont  achev6s ou p""uq-rro. Les disf ositions  n6cessaixes 'pourraient main-
tenant se r6f6'iei  d"trs les six  pays A ces normes et protocofes uniforme.
:.,, ,  ou l-es reprend,re comme parti-e int6grante. 
r
.  Une fois  d6jd, en 195?; la  Commission a rappel6 au Conseil la  n6cessit6
dtracc6l6rer les  d6lib6rations et  demand6 drinscrire  ce point i. lrordre  du j
du Conseil ,de rninistres. $11" a dri constater que ses efforts  sont rest6s sa^-
succds c
.  La Cornmission entreprond maintenant une inj-tiative  nouvel-le et plus vi-
goureuse. ElIe ne dissimule dtailleurs  pas son intention  drentamer 1a proc6dur(Yr,,.
-g-
pr6vue A lrarticl-e  159 du trait6  contre les  gouvernements d6fai.ll-ants srils
persistent A ne pa6 renplir  leure obligatj"ons. La Comrnission est dtavis que
sur la  base des connaissances acguises, une solution gLobale 6gui-1ibr6e,
tenant eompte de tous les int6r6ts  l6gitirnes,  est possible. II  rreut €tre
tenu cornpte A la  fois  des exig.ences de J.a sant6 publique et des j-nt6r6ts
6conomiques. ElIe pense que cet objectif  ne pourra 6tr"e 16a1is6 rapidement
que sl  le  Conseil a.dopte encore au cours de cet automne un programme de
travail  pr6cis et un calendrier fixe.  Crest pourquoi el1e a propos6 au
Conseil Ie progra irrne suivant !
1, D6ci$rqns ,i :rlgn{rq__pg: Le Cgnsei4
Avant Ie  1er .ianvier 1970 :
-  ggcp_tfgg de la  26me directive  (eoncernant l-a dernande drautorisation de
mise sur 1e march6, les  contr6l-es des sp6cialit6s  pharunaceutiques par
l.e fabricant  ainsi  que Ia  surveillance) i  .
- g|gpt_ioq de Ia  Jbme directive  (concernant la  reconnaissance rSciproque
des autorisations de rnise sur lL. march6) ;
Avant Ie  1er .janvier 1971 :
-  a4op_tion  d.e Ia  directive  concernant }a publicit6  des sp6cialit6s  pharma-
ceutiques et J-a notiee.
Ava.nt ]-e 1er janvier  19?3 :
-  adoptig+ des autres directives encore nticessaires en vue de la r6alisa-
tlon ,iT[n march6 conmun des sp6cia]-it6s pharmaceutiquee (voir polnt 2
du prograrnme).
2.  Fropgsitions d. S+ir,e pql la  Conntission
Avant le  1er jjrnvicr  19JZ t
-  pr6sentati on des autres propositions  de directives  dans les  domainee  oti
un rapprochenent des dj-sposj"tions J-6gisl-atives, rdglernentaires et ad-
ministratives  est encore encore n6cessaire  en vue de Ia r6alisation  dtun
march6 comnun des sp6cialit6s  pharmaceutiques (conditions de d6livrance
des m6dicarnents, prj-x1 brevetabih-t6)  ;
Avant 1e 1er ianvier  1975 2
ggg3ligg de la  dj-rective relative'au  r,approchement
concernant les matidres pouvant 6tre ajout6es aux
tigues en vue de leur  colorati-on;
ad.optj-on des dispositions relatives  aux normes et
lcs  rd,sultats des essais.
-  pr6sentatj-on de propositj-ons -  faites  sur Ia  base
gnenenta d6gag6e de lrapplication  de la  directive




drun examen des enoei-
concernant la  reco[-
la  proc6dure de valide-
europ6ennes dj-recten€ri  L tion soit institu6-. une proc6dure drautorlsationsp
-q-
],  I4ise_ en effective  des r6giementatio4S -ad
+: ^^ 1e Conseil
-  i  partif-4u -lee janvier  1971 ;
-  awlication  d9 1a ldre directive  (concernant lrautorisation  de mise
sui: fe march6)
- appllcqtlg{r  de la  26me directive  (concernant les contrbLes) i
-  mise en place d. tune 6troj-te col.l.aboration entre les autorit6s  comp6-
tentes des Etats nembres, notarnm.ent pour 6changer les  enseignements
qui se d6gagent de l-tapplication  des deux preinibres directives'
-  a gar.ti.r du 1el-jaurfer  1972, :
- aqpl*calipn  de 1a directive  concernant les colorants  ;
- applig*jjlog de 1a Jdrne directive  (concernant l-a reconnaissance  r6cj--
p?6-qu*t?-s "utorisations 
de ntise 6ur le  march6)'
-  €xao€rt des cas parti-culiers  dans lesquels 1a d6livrance ou 1e retrait
drautorisation de mise sur Ie  march6p fait  conform6ment au droit  Ta.p+
proch6, donne lieu  Er des divergences de vues entre les Etats meubres.
- i-partir  du ,1er,,-j.anvier  197? :
-  appllgation de la  directive  concernant la  publicit6'
-  d. oartir  du 1er ianvier  19?4 3
-  application drautres directives  encore n6cessaires pour r6a1j-ser un
ffififiqfiffiun des sp6cialit6s pharmaceutiques.